RECOMBINANT HUMAN INTERFERON-GAMMA IN PATIENTS WITH RHEUMATOID-ARTHRITIS

  • 1 May 1986
    • journal article
    • research article
    • Vol. 45  (3) , 93-99
Abstract
In a clinical phase II trial the efficacy and side effects of recombinannt human interferon gamma in 13 patients with rheumatoid arthritis (RA) are reported, 2 patients (15.3%) showed a marked improvement of rest- and motion pains and of their general motility after 6 and 8 month treatment. Only a temporary impromevent within 2-3 months was observed in 4 patients (30.7%). In 2 cases a reduction of the erythrocyte sedimenation rate and in 4 cases a reduction of the alpha-1 acid glycoprotien and of the number of thrombocytes was documented parallel to the clinical improvement, 3 patients developed new antinuclear antibodies (ANA) or showed an increased titer of ANA. Fever was the most common side effects followed by lymphopenia and increased liver values. All side effects were reversible after dosage reduction. Our results confirm the relatively good short term efficacy of human recombinant interferon gamma in RA. In contrast, the clinical long term benefit remains doubtful.

This publication has 1 reference indexed in Scilit: